ACHE and Alzheimer disease: encapsulated the hydrophilic rivastigmine in a sodium-taurocholate liposomal carrier and established its enhanced AChE inhibitory activity compare to its free form due to its sustained pharmacokinetic (PK) profile in an AD mouse model (Mutlu et al., 2011).